Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 75-86

  Stoof, Johannes C ^a   Winogrodzka, Ania ^a   Van Muiswinkel, Freek L ^a   Wolters, Erik Ch ^a   Voorn, Pieter ^a   Groenewegen, Henk J ^a   Booij, J ^b   Drukarch, Benjamin ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Brain imaging; Neuroprotection; Oxidative stress; Parkinson's disease; Treatment efficacy

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; GLUTATHIONE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; PERGOLIDE;

AUTOOXIDATION; BRAIN SCINTISCANNING; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; DIAGNOSTIC IMAGING; DOPAMINE; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0032981205     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00260-5     Document Type: Review

References (104)

1. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
2. Alexander G.E., Crutcher M.D., DeLong M.R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog. Brain Res. 85:1990;119-146.
3. Amara A., Coussemacq M., Geffard M. Antibodies to reduced glutathione. Brain Res. 659:1994;237-242.
4. Andringa G., Vermeulen R.J., Drukarch B., Stoof J.C., Cools A.R. Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease. Adv. Pharmacol. 42:1998;792-795.
5. Andringa, G., Vermeulen, R.J., Drukarch, B., Renier, W.O., Stoof, J.C., Cools, A.R., 1999. The validity of the pretreated, unilaterally MPTP-treated monkey as model of Parkinson's disease: a detailed behavioral analysis of the therapeutic and undesired effects of the D2 agonist LY 171555 and the D1 agonist SKF 81927. Behavioural Pharmacol., in press.
6. Andringa, G., Lubbers, L., Drukarch, B., Stoof, J.C., Cools, A.R., 1999. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82959. Behavioural Pharmacol., in press.
7. Ansher S.S., Dolan P., Bueding E. Biochemical effects of dithiolthiones. Food Chem. Toxicol. 24:1986;405-415.
8. Baez S., Segura-Aguilar J., Widersten M., Johansson A.-S., Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324:1997;25-28.
9. Barone P., Bankiewicz S., Corsini G.U., Kopin I.J., Chase T.N. Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology. 37:1987;1592-1595.
10. Bedard P., Boucher R. Effect of D1 receptor stimulation in normal and MPTP monkeys. Neurosci. Lett. 104:1989;223-228.
11. Bhatia K.P., Marsden C.D. The behavioural and motor consequences of focal lesions of the basal ganglia. Brain. 117:1994;859-876.
12. Bindoli A., Rigobello M.P., Deeble D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radical Biol. Med. 13:1992;391-405.
13. Blanchet P.J., Grondin R., Bedard P.J., Shiosaki K., Britton D.R. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. Eur. J. Pharmacol. 309:1996;13-20.
14. 123I ]FP-CIT SPECT shows pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease J. Neurol., Neurosurg. Psychiatry. 62:1997;133-140.
15. Booij, J., Winogrodzka, A., Bergmans, P., Wolters, E.C., Stoof, J.C., van Royen, E.A., 1999. [I-123]-beta-CIT and [I-123]FP-CIT SPECT are useful methods to monitor progression of dopaminergic degeneration in early-stage Parkinson's disease. (Abstract 46th annual Meeting Society of Nuclear Medicine). J. Nucl. Med., in press.
16. 18F -DOPA uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Ann. Neurol. 28:1990;547-555.
17. 123I ]beta-CIT: binding kinetics in the human brain J. Neural Transm.: Gen. Sect. 94:1993;137-146.
18. Cheng F.-C., Kuo J.-S., Chia L.-G., Dryhurst G. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural Transm. 103:1996;433-446.
19. Christen M.-O. Anethole dithiolethione: biochemical considerations. Methods Enzymol. 252:1995;316-323.
20. Damier P., Hirsch E.C., Zhang P., Agid Y., Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 52:1993;1-6.
21. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
22. de Long M.J., Dolan P., Santamaria A.B., Bueding E. 1,2-dithiol-3-thione analogs: effects on NAD(P)H:quinone reductase and glutathione levels in murine hepatoma cells. Carcinogenesis. 7:1986;977-980.
23. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H.V., Jenner P., Marsden C.D. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:1994;38-44.
24. D'Ischia M., Prota G. Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigm. Cell Res. 10:1997;370-376.
25. Dringen R., Hamprecht B., Drukarch B. Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;616-622.
26. Drukarch B., Schepens E., Stoof J.C., Langeveld C.H. Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes. Eur. J. Pharmacol. 329:1997;259-262.
27. Duffy S., So A., Murphy T.H. Activation of endogeneous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J. Neurochem. 71:1998;69-77.
28. Egner P.A., Kensler T.W., Prestera T., Talalay P., Libby A.H., Joyner H.H., Curphey T.J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis. 15:1994;177-181.
29. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:1992;804-812.
30. Fischman A.J., Bonab A.A., Babich J.W., Palmer E.P., Alpert N.M., Elmaleh D.R., Callahan R.J., Barrow S.A., Graham W., Meltzer P.C., Hanson R.N., Madras B.K. Rapid detection of Parkinson's disease by SPECT with atropane: a selective ligand for dopamine transporters. Synapse. 29:1998;128-141.
31. Fornstedt B., Brun A., Rosengren E., Carlsson A. The apparent autooxidation rate of catechols in dopamine-rich regions of human brain increases with the degree of depigmentation of substantia nigra. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 1:1989;279-295.
32. Frey K.A., Koeppe R.A., Kilbourn M.R., vanderBorght T.M., Albin R.L., Gilman S., Kuhl D.E. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40:1996;873-884.
33. Gerfen C.R. The neostriatal mosaic: multiple levels of organization. Trends Neurosci. 15:1992;133-139.
34. Gerfen C.R., Young W.S. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167.
35. Gibb W.R.G., Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differentiated cell death in Parkinson's disease. J. Neurol., Neurosurg. Psychiatry. 54:1991;388-396.
36. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
37. Groenewegen H.J., Berendse H.W., Wolters J.G., Lohman A.H.M. The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. Prog. Brain Res. 85:1990;95-118.
38. Groenewegen, H.J., Roeling, T.A.P., Voorn, P., Berendse, H.W., 1993. The parallel arrangement of basal ganglia-thalamocortical circuits: a neuronal substrate for the role of dopamine in motor and cognitive functions. In: Wolters, E.C., Scheltens, P. (Eds.), Mental Dysfunction in Parkinson's Disease. ICG Dordrecht, The Netherlands, pp. 3-18.
39. Hagan J.J., Middlemiss D.N., Sharpe P.C., Poste G.H. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol. Sci. 18:1997;156-163.
40. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 334:1988;345-348.
41. Hjelle O.P., Chaudhry F.A., Ottersen O.P. Antisera to glutathione: characterization and immunocytochemical application to rat cerebellum. Eur. J. Neurosci. 6:1994;793-804.
42. Innis R.B., Seibyl J.B., Scanley B.E., Laruelle M. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11965-119694.
43. Itoh Y., Fujita M., Shimada S., Watanabe Y., Okada T., Kusuoka H., Tohyama M., Nishimura T. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse. 31:1999;178-186.
44. Jaiswal A.K. Antioxidant response element. Biochem. Pharmacol. 48:1994;439-444.
45. Jellinger K. Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14:1991;153-160.
46. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:1998;S72-S84. Suppl.
47. Jenner P., Dexter D.T., Sian I., Schapira A.H., Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32:1992;582-587.
48. Kaufman M.J., Madras B.K. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse. 9:1991;43-49.
49. Kazumata K., Dhawan V., Chaly T., Antonini A., Margouleff C., Belakhlef A., Neumeyer J., Eidelberg D. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J. Nucl. Med. 39:1998;1521-1530.
50. Kebabian J.W., Britton D.R., DeNinno M.P., Perner R., Smith L., Jenner P., Schoenleber R., Williams M. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur. J. Pharmacol. 229:1992;203-209.
51. Khanna S., Sen C.K., Roy S., Christen M.-O., Packer L. Protective effects of anethole dithiolethione against oxidative stress-induced cytotoxicity in human jurkat T cells. Biochem. Pharmacol. 56:1998;61-69.
52. Kish S.J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58:1985;343-346.
53. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 876:1988;876-880.
54. Langeveld C.H., Schepens E., Jongenelen C.A.M., Stoof J.C., Hjelle O.P., Ottersen O.P., Drukarch B. Presence of glutathione immunoreactivity in cultured neurones and astrocytes. NeuroReport. 7:1996;1833-1836.
55. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 311:1995;1602-1607.
56. Li H., Shen X.-M., Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J. Neurochem. 71:1998;2049-2062.
57. Lind C., Hochstein P., Ernster L. DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch. Biochem. Biophys. 216:1982;178-185.
58. Makar T.K., Nedergaard M., Preuss A., Gelbhard A.S., Perumal A.S., Cooper A.J.L. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem. 62:1994;45-53.
59. Marsden C.D., Obeso J.A. The functions of basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain. 117:1994;877-897.
60. Maxuitenko Y.Y., Libby A.H., Joyner H.H., Curphey T.J., MacMillen D.L., Kensler T.W., Roebuck B.D. Identification of dithiolethiones with better chemopreventive properties than oltipraz. Carcinogenesis. 19:1998;1609-1615.
61. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 52:1983;711-760.
62. Meyer U.A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm. 24:1996;449-459.
63. 18F ] DOPA PET findings in early Parkinson's disease J. Neurol., Neurosurg. Psychiatry. 59:1995;597-600.
64. Morrish et al., 1996.
65. 18F ]DOPA PET J. Neurol., Neurosurg. Psychiatry. 64:1998;314-319.
66. Muller W.H., Freimuller-Kreutzer B. Induction of γ-glutamyltransferase in cultured brain cells. Biol. Chem. Hoppe-Seyler. 366:1985;375-378.
67. Murphy T.H., So A.P., Vincent S.R. Histochemical detection of quinone reductase activity in situ using LY 83583 reduction and oxidation. J. Neurochem. 70:1998;2156-2164.
68. Muthane U., Yasha T.C., Shankar S.K. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains in India. Ann. Neurol. 43:1998;283-287.
69. O'Dwyer P.J., Szarka C.E., Yao K.-S., Halbherr T.C., Pfeiffer G.R., Green F., Gallo J.M., Brennan J., Frucht H., Goosenberg E.B., Hamilton T.C., Litwin S., Balshem A.M., Engstrom P.F., Clapper M.L. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J. Clin. Invest. 98:1996;1210-1217.
70. Parkinson Study Group, 1989 DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch. Neurol. 46:1989;1052-1060.
71. Parkinson Study Group, 1993 Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
72. Philbert M.A., Beiswanger C.M., Manson M.M., Green J.A., Novak R.F., Primiano T., Reuhl K.R., Lowndes H.E. Glutathione S-transferases and γ-glutamyl transpeptidase in the rat nervous system: a basis for differential susceptibility to neurotoxicants. Neurotoxicology. 16:1995;349-362.
73. Pifl C., Nanoff G., Schingnitz G., Schutz W., Hornykiewicz O. Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of MPTP-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J. Neurochem. 58:1992;1997-2004.
74. Primiano T., Kensler T.W., Kuppusamy P., Zweier J.L., Sutter T. Induction of hepatic heme oxygenase-1 and ferritin in rats by cancer chemopreventive dithiolethiones. Carcinogenesis. 17:1996;2291-2296.
75. Primiano, T., Sutter, T., Kensler, T.W., 1997. Antioxidant-inducible genes. In: Sies, H. (Ed.), Antioxidants in Disease Mechanisms and Therapy, Adv. Pharmacol., Academic Press, Vol. 38, pp. 293-328.
76. Raps S.P., Lai J.C.K., Hertz L., Cooper A.J.L. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 493:1989;398-401.
77. Ravindranath V., Anandatheerthavarada H.K., Shankar S.K. NADPH Cytochrome P-450 reductase in rat, mouse and human brain. Biochem. Pharmacol. 39:1990;1013-1018.
78. Segura-Aguilar J. Peroxidase activity of liver microsomal vitamin D 25-hydroxylase and cytochrome P450 1A2 catalyzes 25-hydroxylation of vitamin D3 and oxidation of dopamine to aminochrome. Biochem. Mol. Med. 58:1996;122-129.
79. Segura-Aguilar J., Baez S., Widersten M., Welch C.J., Mannervik B. Human class mu glutathion transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J. Biol. Chem. 272:1997;5727-5731.
80. Segura-Aguilar J., Metodiewa D., Welch C.J. Metabolic activation of dopamine o-quinones to o-semiquinone by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotics effects. Biochem. Biophys. Acta. 1381:1998;1-6.
81. Schultzberg M., Segura-Aguilar J., Lind C. Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience. 27:1988;763-776.
82. Shiosaki K., Asin K.E., Britton D.R., Giardina W.J., Bednarz L., Mahan L., Mikusa J., Nikkel A., Wismer C. Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431. Eur. J. Pharmacol. 317:1996;183-190.
83. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
84. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., Marsden C.D. Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36:1994;356-361.
85. Slivka A., Mytilineou C., Cohen G. Histochemical evaluation of glutathione in brain. Brain Res. 409:1987;275-284.
86. Smythies J., Galzigna L. The oxidative metabolism of catecholamines in the brain: a review. Biochem. Biophys. Acta. 1380:1998;159-162.
87. Spencer J.P.E., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71:1998;2112-2122.
88. Starr M.S., Starr B.S. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J. Neural Transm.: Parkinson's Dis. Dementia Sect. 6:1993;27-34.
89. Stoof J.C., Kebabian J.W. Opposing roles for D1 and D2 receptors in efflux of cyclic AMP from rat striatum. Nature. 294:1981;366-368.
90. Strange P.G. New insights into dopamine receptors in the central nervous system. Neurochem. Int. 22:1993;223-236.
91. Taylor J.R., Lawrence M.S., Redmond D.E., Elsworth J.D., Roth R.H., Nichols D.E., Mailman R.B. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. 199:1991;389-391.
92. 123I ]beta-CIT SPECT in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls Eur. J. Nucl. Med. 24:1997;1171-1174.
93. Tissingh G., Booij J., Bergmans P., Winogrodzka A., Janssen A.G., van Royen E.A., Stoof J.C., Wolters E.C. Iodine-123-N-omega-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug naive Parkinson's disease. J. Nucl. Med. 39:1998;1143-1148.
94. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Wallace E., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Charney D.S., Hoffer P.B., Innis R.B. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J. Nucl. Med. 36:1995;1175-1181.
95. van Lieshout E.M.M., Tiemessen D.M., Roelofs H., Peters W.H.M. Nonsteroidal anti-inflammatory drugs enhance glutathione S-transferase theta levels in rat colon. Biochim. Biophys. Acta. 1381:1998;305-311.
96. Vermeulen R.J., Drukarch B., Sahadat M.C.R., Wolters E.C., Stoof J.C. The selective D1 receptor agonist SKF 81297 stimulates motor behavior of MPTP-lesioned monkeys. Eur. J. Pharmacol. 235:1993;143-147.
97. Vermeulen R.J., Jongenelen C.A.M., Langeveld C.H., Wolters E.C., Stoof J.C., Drukarch B. Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes. Eur. J. Pharmacol. 269:1994;121-125.
98. 123I ]-beta-CIT binding with SPECT in controls, early and late Parkinson's disease Nucl. Med. Biol. 22:1995;985-991.
99. Vingerhoets F.J.G., Snow B.J., Lee C.S., Schulzer M., Mak E., Calne D.B. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. Ann. Neurol. 36:1994;759-764.
100. Waddington J.L., O'Boyle K.M. Drugs acting on dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacol. Therapeutics. 43:1989;1-52.
101. Wang W., Liu L.Q., Higuchi C.M., Chen H. Induction of NADPH:quinone reductase by dietary phytoestrogens in colonic Colo205 cells. Biochem. Pharmacol. 56:1998;189-195.
102. Wilkinson J., Clapper M.L. Detoxication enzymes and chemoprevention. Proc. Soc. Exp. Biol. Med. 216:1997;192-200.
103. Wolters, E.C., 1992. In: Agid, Y. (Ed.), Current trends in the treatment of Parkinson's disease. John Libbey, London, UK, pp. 39-52.
104. Zhang Y., Talalay P., Cho C.-G., Posner G.H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. U.S.A. 89:1992;2399-2403.